vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and REGIS CORP (RGS). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($71.7M vs $57.1M, roughly 1.3× REGIS CORP). REGIS CORP runs the higher net margin — 0.8% vs -18.9%, a 19.7% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 22.3%). Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $891.0K). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs 7.8%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
ADPT vs RGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $57.1M |
| Net Profit | $-13.6M | $456.0K |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | 10.8% |
| Net Margin | -18.9% | 0.8% |
| Revenue YoY | 51.0% | 22.3% |
| Net Profit YoY | 59.7% | -94.0% |
| EPS (diluted) | $-0.08 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $57.1M | ||
| Q3 25 | $94.0M | $59.0M | ||
| Q2 25 | $58.9M | $60.4M | ||
| Q1 25 | $52.4M | $57.0M | ||
| Q4 24 | $47.5M | $46.7M | ||
| Q3 24 | $46.4M | $46.1M | ||
| Q2 24 | $43.2M | $49.4M | ||
| Q1 24 | $41.9M | $49.2M |
| Q4 25 | $-13.6M | $456.0K | ||
| Q3 25 | $9.5M | $1.4M | ||
| Q2 25 | $-25.6M | $116.5M | ||
| Q1 25 | $-29.9M | $250.0K | ||
| Q4 24 | $-33.7M | $7.6M | ||
| Q3 24 | $-32.1M | $-853.0K | ||
| Q2 24 | $-46.2M | $91.2M | ||
| Q1 24 | $-47.5M | $-2.3M |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | 10.8% | ||
| Q3 25 | 10.9% | 10.0% | ||
| Q2 25 | -42.5% | 12.1% | ||
| Q1 25 | -56.4% | 8.8% | ||
| Q4 24 | -71.3% | 11.8% | ||
| Q3 24 | -70.3% | 4.6% | ||
| Q2 24 | -109.6% | — | ||
| Q1 24 | -116.5% | 8.3% |
| Q4 25 | -18.9% | 0.8% | ||
| Q3 25 | 10.2% | 2.3% | ||
| Q2 25 | -43.5% | 192.9% | ||
| Q1 25 | -56.9% | 0.4% | ||
| Q4 24 | -71.0% | 16.4% | ||
| Q3 24 | -69.1% | -1.9% | ||
| Q2 24 | -107.0% | 184.7% | ||
| Q1 24 | -113.5% | -4.7% |
| Q4 25 | $-0.08 | $0.16 | ||
| Q3 25 | $0.06 | $0.49 | ||
| Q2 25 | $-0.17 | $43.67 | ||
| Q1 25 | $-0.20 | $0.08 | ||
| Q4 24 | $-0.22 | $2.71 | ||
| Q3 24 | $-0.22 | $-0.36 | ||
| Q2 24 | $-0.31 | $38.40 | ||
| Q1 24 | $-0.33 | $-1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $18.4M |
| Total DebtLower is stronger | — | $113.3M |
| Stockholders' EquityBook value | $218.8M | $188.7M |
| Total Assets | $512.7M | $588.3M |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $18.4M | ||
| Q3 25 | $55.0M | $16.6M | ||
| Q2 25 | $43.2M | $17.0M | ||
| Q1 25 | $50.6M | $13.3M | ||
| Q4 24 | $47.9M | $10.2M | ||
| Q3 24 | $38.1M | $6.3M | ||
| Q2 24 | $59.8M | $10.1M | ||
| Q1 24 | $71.2M | $5.9M |
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
| Q4 25 | $218.8M | $188.7M | ||
| Q3 25 | $204.4M | $187.6M | ||
| Q2 25 | $179.7M | $185.6M | ||
| Q1 25 | $190.4M | $68.6M | ||
| Q4 24 | $202.7M | $66.7M | ||
| Q3 24 | $223.8M | $56.4M | ||
| Q2 24 | $241.6M | $56.8M | ||
| Q1 24 | $274.9M | $-35.8M |
| Q4 25 | $512.7M | $588.3M | ||
| Q3 25 | $490.6M | $592.1M | ||
| Q2 25 | $496.6M | $599.0M | ||
| Q1 25 | $510.9M | $511.2M | ||
| Q4 24 | $539.4M | $530.1M | ||
| Q3 24 | $558.5M | $508.9M | ||
| Q2 24 | $584.9M | $530.5M | ||
| Q1 24 | $620.3M | $543.7M |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $1.7M |
| Free Cash FlowOCF − Capex | $1.4M | $891.0K |
| FCF MarginFCF / Revenue | 2.0% | 1.6% |
| Capex IntensityCapex / Revenue | 0.9% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 3.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $1.7M | ||
| Q3 25 | $-7.1M | $2.3M | ||
| Q2 25 | $-12.4M | $6.8M | ||
| Q1 25 | $-28.5M | $6.2M | ||
| Q4 24 | $-12.5M | $2.1M | ||
| Q3 24 | $-27.1M | $-1.3M | ||
| Q2 24 | $-17.3M | $5.1M | ||
| Q1 24 | $-38.4M | $-277.0K |
| Q4 25 | $1.4M | $891.0K | ||
| Q3 25 | $-7.5M | $1.9M | ||
| Q2 25 | $-13.1M | $6.2M | ||
| Q1 25 | $-29.7M | $5.9M | ||
| Q4 24 | $-12.6M | $1.7M | ||
| Q3 24 | $-27.4M | $-1.4M | ||
| Q2 24 | $-19.0M | $5.1M | ||
| Q1 24 | $-39.9M | $-326.0K |
| Q4 25 | 2.0% | 1.6% | ||
| Q3 25 | -8.0% | 3.2% | ||
| Q2 25 | -22.2% | 10.3% | ||
| Q1 25 | -56.7% | 10.3% | ||
| Q4 24 | -26.5% | 3.6% | ||
| Q3 24 | -59.0% | -3.0% | ||
| Q2 24 | -44.1% | 10.3% | ||
| Q1 24 | -95.2% | -0.7% |
| Q4 25 | 0.9% | 1.4% | ||
| Q3 25 | 0.4% | 0.7% | ||
| Q2 25 | 1.1% | 0.9% | ||
| Q1 25 | 2.4% | 0.6% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 0.7% | 0.0% | ||
| Q2 24 | 4.0% | 0.0% | ||
| Q1 24 | 3.6% | 0.1% |
| Q4 25 | — | 3.65× | ||
| Q3 25 | -0.75× | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
